Xeris制药(XERS)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

XERS Xeris制药

交易中 07-22 14:23:02 EDT

2.42

+0.05

+2.11%

最高2.43	最低2.33	成交量47.28万
今开2.35	昨收2.37	日振幅4.23%
总市值3.58亿	流通市值3.47亿	总股本1.48亿
成交额112.49万	换手率0.33%	流通股本1.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris制药","latestPrice":2.415,"timestamp":1721672533953,"preClose":2.365,"halted":0,"volume":472835,"delay":0,"floatShares":143828155,"shares":148255663,"eps":-0.464929,"marketStatus":"交易中","marketStatusCode":2,"change":0.05,"latestTime":"07-22 14:23:02 EDT","open":2.35,"high":2.43,"low":2.33,"amount":1124911.535264,"amplitude":0.042283,"askPrice":2.42,"askSize":2034,"bidPrice":2.41,"bidSize":2030,"shortable":3,"etf":0,"ttmEps":-0.464929,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721678400000},"adr":0,"listingDate":1529553600000,"adjPreClose":2.365,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":2.36,"preClose":2.365,"latestTime":"09:25 EDT","volume":947,"amount":2235.9199373,"timestamp":1721654700038},"postHourTrading":{"tag":"盘后","latestPrice":2.35,"preClose":2.365,"latestTime":"16:41 EDT","volume":4627,"amount":10940.125,"timestamp":1721421660736},"volumeRatio":0.503694,"impliedVol":0.9877,"impliedVolPercentile":0.5737},"requestUrl":"/m/hq/s/XERS/tweets","defaultTab":"tweets","newsList":[{"id":"2434304913","title":"Xeris 生物制药控股公司公布截至一月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2434304913","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434304913?lang=zh_cn&edition=full","pubTime":"2024-05-10 02:43","pubTimestamp":1715280215,"startTime":"0","endTime":"0","summary":"   * Xeris Biopharma Holdings Inc   报告，截至1月底的季度调整后每股亏损14美分，低于去年同期的每股收益-12美分。六位分析师对该季度的平均预期是每股亏损 12 美分。华尔街预期为每股-14美分至-11美分。* Xeris Biopharma Holdings Inc公布的本季度每股收益为亏损14美分。* 该公司当季亏损 1898 万美元。* Xeris Biopharma Holdings Inc 的股价本季度下跌了 16.3%，今年迄今为止下跌了 21.3%。* 医药同行的平均一致建议是 \"买入\"。华尔街对 Xeris Biopharma Holdings Inc 的 12 个月目标价中位数为 4.75 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2433247733","title":"Xeris Biopharma Holdings Inc   预计每股亏损12美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2433247733","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433247733?lang=zh_cn&edition=full","pubTime":"2024-05-08 01:56","pubTimestamp":1715104612,"startTime":"0","endTime":"0","summary":"   * Xeris Biopharma Holdings Inc    将于5月9日公布截至2001年1月1日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，6位分析师的平均预期显示，这家总部位于芝加哥伊利诺伊州的公司的营收预计将从去年同期的3320万美元增长26.0%，达到4181.5万美元。* LSEG 分析师对 Xeris Biopharma Holdings Inc 的平均预期是每股亏损 12 美分。* 华尔街对 Xeris Biopharma Holdings Inc 的 12 个月目标价中位数为 4.75 美元，高于其上一次收盘价 1.90 美元。5月7日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"2417529213","title":"Xeris 生物制药控股公司公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2417529213","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417529213?lang=zh_cn&edition=full","pubTime":"2024-03-06 22:42","pubTimestamp":1709736121,"startTime":"0","endTime":"0","summary":"   * Xeris Biopharma Holdings Inc   报告了截至12月底的季度调整后每股亏损10美分，与去年同期持平。华尔街预期为每股-13美分至-7美分。* 营收同比增长 33.9%，达到 4439 万美元；分析师预期为 4355 万美元。* Xeris Biopharma Holdings Inc公布的本季度每股收益为亏损10美分。* Xeris Biopharma Holdings Inc 的股价本季度上涨了 31.1%。3月6日 - 预测变化   * 在过去三个月中，分析师的平均盈利预测上升了约 3.9%。* 生物技术和医学研究同行的平均一致建议也是 \"买入\"。华尔街对 Xeris Biopharma Holdings Inc 的 12 个月目标价中位数为 4.50 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2416147731","title":"Xeris Biopharma Holdings Inc   预计每股亏损10美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2416147731","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416147731?lang=zh_cn&edition=full","pubTime":"2024-03-04 23:05","pubTimestamp":1709564729,"startTime":"0","endTime":"0","summary":"   * Xeris Biopharma Holdings Inc    将于3月6日公布截至2023年12月31日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，4位分析师的平均预期显示，这家总部位于芝加哥伊利诺伊州的公司的营收预计将从去年同期的3314万美元增长31.4%，达到4355.2万美元。   * LSEG 分析师对 Xeris Biopharma Holdings Inc 的平均预期是每股亏损 10 美分。* 华尔街对 Xeris Biopharma Holdings Inc 的 12 个月目标价中位数为 4.50 美元，高于其上一次收盘价 3.18 美元。3月4日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.1103},{"period":"3month","weight":0.3592},{"period":"6month","weight":-0.0187},{"period":"1year","weight":-0.0833},{"period":"ytd","weight":0.0064}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Xeris Biopharma Holdings, Inc.于2005年根据特拉华州的法律成立。该公司致力于打造一家创新的、自我维持的、以增长为导向的生物制药公司，致力于通过开发一系列疗法中具有临床意义的产品并将其商业化来改善患者的生活。该公司具有独特的优势，通过三种商业产品和专有配方科学（XeriSol和XeriJect）来实现这一目标，从而建立合作伙伴关系并增强候选产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.091365},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.026041},{"month":3,"riseRate":0.5,"avgChangeRate":-0.107706},{"month":4,"riseRate":0.5,"avgChangeRate":0.063543},{"month":5,"riseRate":0.666667,"avgChangeRate":0.186811},{"month":6,"riseRate":0.5,"avgChangeRate":-0.069518},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.031358},{"month":8,"riseRate":0.5,"avgChangeRate":0.165434},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.094375},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.059108},{"month":11,"riseRate":0.5,"avgChangeRate":0.006729},{"month":12,"riseRate":0.5,"avgChangeRate":0.047808}],"exchange":"NASDAQ","name":"Xeris制药","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris制药(XERS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Xeris制药(XERS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Xeris制药,XERS,Xeris制药股票,Xeris制药股票老虎,Xeris制药股票老虎国际,Xeris制药行情,Xeris制药股票行情,Xeris制药股价,Xeris制药股市,Xeris制药股票价格,Xeris制药股票交易,Xeris制药股票购买,Xeris制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris制药(XERS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Xeris制药(XERS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况